Navigation Links
Jefferson researcher receives 2010 Pancreatic Cancer Action Network-AACR Career Development Award
Date:4/13/2010

PHILADELPHIA Molecular biologist Jonathan Brody, Ph.D., assistant professor, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, has been awarded a 2010 Pancreatic Cancer Action Network American Association of Cancer Research (AACR) Career Development Award in memory of Skip Viragh. This two-year grant awards $200,000 to Dr. Brody to help support his innovative research in pancreatic cancer. He will receive recognition for his work at the 2010 AACR annual meeting in Washington, D.C. on April 20th.

"As a young pancreatic cancer researcher I have always admired these two top-notch organizations," says Dr. Brody. "To be recognized by them truly is an honor and validates the direction of my research."

This award allows him to produce a body of high-quality data over the next few years as he strives to extend his funding and work with the aid of such agencies as the National Cancer Institute (NCI). Ultimately, Dr. Brody hopes this funding will help translate the work in his laboratory for the benefit of pancreatic cancer patients in the clinical setting.

Dr. Brody will use the funding to build upon his research on a stress-response protein called Hu antigen R (HuR), "activated' in pancreatic tumor cells. Dr. Brody and his team have found that HuR can actually be used to predict the effectiveness of the standard chemotherapy treatment for pancreatic cancer: gemcitabine. Dr. Brody and his team are now seeking a way to activate HuR in patients that show low levels of the protein. "The research is moving into expanding our clinical samples as well as building on pre-clinical, animal models for further exploration," says Dr. Brody. "We are intrigued as to whether other chemotherapeutic agents might also engage this same pathway."

This means that HuR is essentially a biomarker, which we can use to determine up front whether a patient is likely to respond to this treatment or not. The findings of his initial study, of which Dr. Brody was the senior author and Dr. Agnieszka Witkiewicz, assistant professor, Department of Pathology, Anatomy and Cell Biology, closely collaborated on, were first published as a Priority Report in the journal Cancer Research in June 2009; a follow up report is being presented at the American Surgical Association in Chicago this April. Dr. Witkiewicz's involvement and expertise has been critical for this work.

"While the need for scientific and medical breakthroughs in pancreatic cancer research is urgent, there is a major shortage of federal funding for research on this deadly disease," says Julie Fleshman, President and CEO of the Pancreatic Cancer Action Network. "Since 1999, the Pancreatic Cancer Action Network has been working to help fill this critical void. In 2010, we will disburse nearly $2.3 million in funding for research grants. We are excited about this partnership with Dr. Brody and look forward to working with him as we make strides against pancreatic cancer ."

"By improving our understanding of drug metabolism and the molecular diversity that exists within the patient population, this study has important implications for the development of personalized medicine for pancreatic cancer," notes Ms. Fleshman. "The results have the potential to help us learn how to customize treatments for patients to improve outcomes and survival."

One of three Career Development Awards granted to junior faculty at academic and medical institutions this year, Dr. Brody's award is named for the philanthropist and Rydex Investments founder Skip Viragh, who died of pancreatic cancer in 2003.


'/>"/>

Contact: Ed Federico
ed.federico@jefferson.edu
Thomas Jefferson University
Source:Eurekalert  

Related medicine news :

1. Jefferson physician named 2010 Emergency Department Director of the Year
2. Jefferson surgeon receives outstanding performance award from American College Of Surgeons
3. Jefferson neurosurgeon helps draft new treatment guidelines for brain metastases
4. Jefferson awarded multi-million dollar NIH grant
5. Researchers find compound effective in destroying antibiotic-resistant biofilms
6. Boston researchers lead $15 million federal research grant to support advancement of health IT
7. Researchers discover new approach for identifying smokers at highest risk for developing lung cancer
8. Researchers aim for consensus on measuring the impact of visual impairment
9. Researchers Boost Post-Heart Attack Survival in Mice
10. Researchers quantify benefits of minimally invasive removal of hard-to-reach tumors
11. Researchers design self-test for memory disorders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Jefferson researcher receives 2010 Pancreatic Cancer Action Network-AACR Career Development Award
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: